ArticleJournal of clinical microbiology2005
Comparison of diagnostic laboratory methods for identification of Burkholderia pseudomallei.
Article in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Current Melioidosis Diagnostic Landscape and Missed Opportunities in Biomarker Development.Diagnostics (Basel, Switzerland) · 2026Review
- Rapid Cavitary Pneumonia and Reversible Hepatic Injury in Burkholderia pseudomallei ST271 Infection.The American journal of case reports · 2026Article
- Laboratory strategies for the identification of Burkholderia species: From classical phenotyping to advanced genomic and proteomic approaches.Antonie van Leeuwenhoek · 2026Review
- Laboratory diagnosis of melioidosis.PLoS neglected tropical diseases · 2025Review
- Fatal Adverse Event After VLA1553 Chikungunya Vaccination in an Elderly Patient: A Case Report From Reunion Island.Open forum infectious diseases · 2025Article
- Disseminated Melioidosis from a Ruptured Infective Aortic Aneurysm and Pedal Ulcers to Septic Arthritis and Osteomyelitis: A Case Report.Vascular specialist international · 2025Article
- A novel ready-to-use loop-mediated isothermal amplification (LAMP) method for detection of Burkholderia mallei and B. pseudomallei.BMC microbiology · 2025Article
- Haemophagocytic lymphohistiocytosis due toAccess microbiology · 2023Article
- Endemic melioidosis in central Taiwan-A longitudinal case cohort study.Frontiers in medicine · 2023Article
- Case of misdiagnosed melioidosis from Hue city, Vietnam.Iranian journal of microbiology · 2022Article
- Article
- Rapid Clinical Screening of Burkholderia pseudomallei Colonies by a Bacteriophage Tail Fiber-Based Latex Agglutination Assay.Applied and environmental microbiology · 2021Article
- Jugular Lymphadenitis as a Precursor toJournal of maxillofacial and oral surgery · 2020Article
- Human Melioidosis.Clinical microbiology reviews · 2020Review
- Medical Devices for Low- and Middle-Income Countries: A Review and Directions for Development.Journal of medical devices · 2020Review
- Evaluation of the Active Melioidosis Detect™ test as a point-of-care tool for the early diagnosis of melioidosis: a comparison with culture in Laos.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2019Article
- Pan-drug-resistant and biofilm-producing strain ofInternational medical case reports journal · 2019Article
- Burkholderia pseudomallei infection presenting with a lung abscess and osteomyelitis in an adult man: A case report.Medicine · 2018Article
- Melioidosis: An Australian Perspective.Tropical medicine and infectious disease · 2018Review
- Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.Journal of clinical microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Limited experience and a lack of validated diagnostic reagents make Burkholderia pseudomallei, the cause of melioidosis, difficult to recognize in the diagnostic microbiology laboratory. We compared three methods of confirming the identity of presumptive B. pseudomallei strains using a collection of Burkholderia species drawn from diverse geographic, clinical, and environmental sources. The 95 isolates studied included 71 B. pseudomallei and 3 B. thailandensis isolates. The API 20NE method identified only 37% of the B. pseudomallei isolates. The agglutinating antibody test identified 82% at first the attempt and 90% including results of a repeat test with previously negative isolates. Gas-liquid chromatography analysis of bacterial fatty acid methyl esters (GLC-FAME) identified 98% of the B. pseudomallei isolates. The agglutination test produced four false positive results, one B. cepacia, one B. multivorans, and two B. thailandensis. API produced three false positive results, one positive B. cepacia and two positive B. thailandensis. GLC-FAME analysis was positive for one B. cepacia isolate. On the basis of these results, the most robust B. pseudomallei discovery pathway combines the previously recommended isolate screening tests (Gram stain, oxidase test, gentamicin and polymyxin susceptibility) with monoclonal antibody agglutination on primary culture, followed by a repeat after 24 h incubation on agglutination-negative isolates and GLC-FAME analysis. Incorporation of PCR-based identification within this schema may improve percentages of recognition further but requires more detailed evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.